Key result
Redo cusp replacement using cryopreserved decellularized glutaraldehyde-treated (CDGT) autopericardium was successfully applied in a pediatric patient.
Case Report (n=1)
Cryopreserved decellularized glutaraldehyde-treated autopericardium can be successfully used for redo aortic valve cusp replacement in pediatric patients to allow for aortic root growth and postpone valve replacement.
In the past decade, aortic valve (AV) repair in children with cusp prolapse has comprised cusp plication, triangular resection and then extension with autopericardium. Although these techniques have been quite reproducible, durability of AV repair (AVRep) in children with a lack of valve tissue, has been challenging with the mean time to a 50% reoperation of 4,4 years (1). In this setting, cusp replacement may occasionally be quite beneficial to allow for aortic root growth and postponement AV replacement (AVR) methods can be safely used precluding their drawbacks for a time (2). We report a successful application of redo cusp replacement to pediatric patient applying cryopreserved decellularized glutaraldehyde-treated (CDGT) autopericardium.
No takes yet. Share an insight, caveat, or question.
Абдурахманов et al. (2024) conducted a case report in Aortic valve disease requiring redo repair (n=1). Cryopreserved decellularized glutaraldehyde-treated (CDGT) autopericardium was evaluated on Successful application of redo cusp replacement. Redo cusp replacement using cryopreserved decellularized glutaraldehyde-treated (CDGT) autopericardium was successfully applied in a pediatric patient.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: